Biofrontera Inc.
BFRI

$7.45 M
Marketcap
$0.81
Share price
Country
$-0.02
Change (1 day)
$2.22
Year High
$0.65
Year Low

Biofrontera Inc., a biopharmaceutical company, engages in the commercialization of pharmaceutical products for the treatment of dermatological conditions in the United States. The company offers Ameluz, which is a prescription drug approved for use in combination with the company's licensor's medical device; and the RhodoLED lamp series for photodynamic therapy for the lesion-directed and field-directed treatment of actinic keratosis of mild-to-moderate severity on the face and scalp. It also Xepi, a prescription cream for the treatment of impetigo. The company was incorporated in 2015 and is headquartered in Woburn, Massachusetts.

etoro

P/B ratio for Biofrontera Inc. (BFRI)

P/B ratio as of 2024: 1356.37

According to Biofrontera Inc.'s latest financial reports and stock price the company's current price-to-sales ratio (TTM) is 1356.37. At the end of 2023 the company had a P/B ratio of 893.65.

P/B ratio history for Biofrontera Inc. from 2019 to 2024

P/B ratio at the end of each year

Year P/B ratio
2024 1356.37
2023 893.65
2022 811.81
2021 11344.83
2020 8777.63
2019 -1774.00